Send This Page By E-mail
Print this page

Managing the Complete Lipid Profile

Released: 11/08

Jointly sponsored by:

The FCG Institute for Continuing Education and Independent Medical Education (IME), LLC gratefully acknowledge an educational grant from Abbott Laboratories in support of this continuing educational resource.

This Slide Resource Kit as part of an educational slide library has been developed and implemented in a scientifically rigorous manner. Due diligence was followed to ensure fair balance and medical accuracy.

Faculty Disclosure Statement
It is the policy of the FCG Institute for Continuing Education to ensure independence, balance, objectivity, and scientific rigor and integrity in all its slide resource kit activities. Faculty must disclose to the participants any significant relationships with commercial companies whose products or devices may be mentioned in faculty presentations or with the commercial supporter of this activity. Disclosure information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations. Faculty disclosure statements can be found with their biographical sketches.

Faculty Disclosure

Dr. Michael Davidson served as the reviewer for this slide kit.

Presentation

Click here to view presentation

Click here to download presentation

Table of Content

• Managing the Complete Lipid Profile – (Title) Slide 1
• Learning Objectives – Slide 2
• Major Clinical Gap: Unmet Medical Needs in Current Dyslipidemia Management – Slides 3-20
  • Epidemiology of CVD – Slides 4-5
  • CVD Death Rates in the US – Slide 6
  • CVD: A Heavy Burden in the US – Slide 7
  • The Current Standard of Care – Slide 8 and Slide 11
  • Residual Risk in Patients Treated With Statins – Slides 9-10
  • The Prevalence of Mixed Dyslipidemia – Slide 12
  • The Association Between TG and HDL-C and CVD Risk – Slide 13-19
  • Summary of Unmet Needs – Slide 20
• Role of Mixed Dyslipidemia in Atherosclerosis – Slides 21-26
• Current Guidelines and Treatment Recommendations – Slides 27-33
  • NCEP ATP III: New Features and Updates – Slides 28-31
  • Lifestyle Modifications – Slide 32
  • Adherence – Slide 33
• Managing the Complete Lipid Profile – Slides 34-42
  • Pharmacologic Options to Manage Mixed Dyslipidemia – Slide 35
  • Meta-analysis of 53 Trials of Fibrates and 30 Trials of Niacin – Slide 36
  • SEACOAST Trial – Slides 37-39
  • OCEANS Study – Slides 40-42
• Recent Atherosclerosis Reduction Trials – Slides 43-49
  • STRADIVARIUS – Slides 44-45
  • CHICAGO – Slides 46-47
  • PERISCOPE – Slides 48-49
• Recent Mixed Dyslipidemia Trials – Slides 50-54
  • ABT-335 – Slides 51-53
  • Treatment of Mixed Dyslipidemia With ER Niacin Combined With a Flushing Pathway Inhibitor – Slides 54
• Summary and Conclusions – Slides 55-56